


This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

**1. – 4. (Canceled)**

**5. (Previously presented)** A compound of formula (I)



wherein:

R<sup>1</sup> is a [2-(cyclopropylcarbonylamino)phenyl]carbonylmethyl or [2-(pyridylcarbonylamino)phenyl]carbonylmethyl group;

R<sup>2</sup> is a methyl group;

R<sup>3</sup> is a 2-buten-1-yl, 3-methyl-2-buten-1-yl, or a 2-butyn-1-yl group; and

R<sup>4</sup> is a (3-aminopiperidin-1-yl) group,

or a prodrug or salt thereof.

**6. (Previously presented)** A compound selected from:

(1) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-(3-methyl-2-

buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine;

(2) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine;

(3) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-aminopiperidin-1-yl)xanthine;

(4) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine;

(5) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-aminopiperidin-1-yl)xanthine; and

(6) 1-[2-(2-{[(pyridin-2-yl)carbonyl]amino}phenyl)-2-oxoethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine,

or a prodrug or salt thereof.

**7. – 10. (Canceled)**

**11. (Original)** The compound of formula (I) according to claim 5, wherein the compound is a physiologically acceptable salt.

**12. (Previously presented)** The compound according to claim 6, wherein the compound is a physiologically acceptable salt.

**13. (Previously presented)** A pharmaceutical composition comprising a compound of

formula (I) according to claim 5 and an inert carrier or diluent.

**14. (Previously presented)** The pharmaceutical composition according to claim 13, wherein the compound of formula (I) is incorporated with the inert carrier or diluent by mixing.

**15. (Canceled)**

**16. (Currently Amended)** A method of treating ~~type I and~~ type II diabetes mellitus, ~~or obesity,~~ comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound according to claim 5 or 6.

**17. (Previously presented)** A method of treating or preventing type II diabetes mellitus or obesity, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound according to claim 5 or 6.

**18. (Previously presented)** A pharmaceutical composition comprising a compound according to claim 6 and an inert carrier or diluent.

**19. (Previously presented)** The pharmaceutical composition according to claim 18, wherein the compound is incorporated with the inert carrier or diluent by mixing.